Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Q-Line Biotec
Price Band
₹326.0–343.0
Issue Size
₹214.48 Cr
Lot Size
400 shares
Min Investment
₹274,400
GMP
+₹112.0 (32.65%)
Issue Price
₹343.0
calendar_month Important Dates
bar_chart Subscription Status
Subscription data unavailable
trending_up Grey Market Premium (GMP)
GMP
+₹112.0
GMP %
+32.65%
Est. Listing
₹455.0
schedule Updated: 14 Jul 2026 15:51
Share GMP:
business About the Company
Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company's key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. As of March 31, 2025, the company had 313 permanent employees. Competitive Strengths: Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control. Diversified product portfolio with focus on IVD industry Widespread distribution network with a presence across all four regions. Long standing relationships with customers. Experienced Promoter and Management team
payments Company Financials (₹ Cr)
As of 2025-12-31
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 561.34 | 455.49 | 339.25 | 251.58 |
| Total Income | 236.50 | 322.58 | 206.45 | 184.81 |
| Profit After Tax | 38.69 | 28.13 | 34.44 | 32.10 |
| EBITDA | 64.23 | 71.32 | 37.63 | 32.98 |
| NET Worth | 229.16 | 189.95 | 161.81 | 127.37 |
| Reserves and Surplus | 212.89 | 188.37 | 160.24 | 125.79 |
| Total Borrowing | 243.85 | 164.95 | 96.91 | 73.65 |
Key Ratios
EPS
₹16.47
NAV
₹120.60
ROE
23.74%
ROCE
17.66%
RoNW
23.74%
P/B Value
2.84
P/E Ratio
20.82
Market Cap
₹800.16 Cr
PAT Margin
8.97%
Debt/Equity
0.87
Promoters
Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 To meet working capital requirements 93.50 2 Repayment of certain borrowing availed by the Company, in part or full 90.00 3 General Corporate Purposes 5.10 4 Issue Expenses 25.89 Total 214.48
info Issue Details
pie_chart Investor Allocation
Registrar
Lead Managers / Book Running
timeline IPO Timeline
Open
21 May 2026
Close
25 May 2026
Allotment
26 May 2026
Listing
29 May 2026